Hisamitsu Pharmaceutical Co. Inc
Hisamitsu Pharmaceutical Co., Inc. manufactures and sells pharmaceuticals in Japan. The company offers OTC products, such as external pain-relieving drugs under the SALONPAS, NOBINOBI, SALONSIP, AIR, SALONPAS, and FEITAS; BUTENALOCK, a remedy for athlete's foot; and ALLEGRA FX, a sinus medication for allergies. It also manufactures and sells quasi-drugs and cosmetics; MOHRUS TAPE and MOHRUS PAP X… Read more
Market Cap & Net Worth: Hisamitsu Pharmaceutical Co. Inc (HPX)
Hisamitsu Pharmaceutical Co. Inc (F:HPX) has a market capitalization of $2.30 Billion (€2.24 Billion) as of March 18, 2026. Listed on the F stock exchange, this Germany-based company holds position #4819 globally and #488 in its home market, demonstrating a 0.63% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Hisamitsu Pharmaceutical Co. Inc's stock price €32.00 by its total outstanding shares 70046729 (70.05 Million).
Hisamitsu Pharmaceutical Co. Inc Market Cap History: 2015 to 2026
Hisamitsu Pharmaceutical Co. Inc's market capitalization history from 2015 to 2026. Data shows growth from $2.65 Billion to $2.30 Billion (0.19% CAGR).
Hisamitsu Pharmaceutical Co. Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Hisamitsu Pharmaceutical Co. Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.01x
Hisamitsu Pharmaceutical Co. Inc's market cap is 0.01 times its annual revenue
1.01x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
0.08x
Hisamitsu Pharmaceutical Co. Inc's market cap is 0.08 times its annual earnings
10.29x
Lower than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $3.29 Billion | $161.85 Billion | $17.78 Billion | 0.02x | 0.18x |
| 2017 | $3.51 Billion | $145.93 Billion | $20.39 Billion | 0.02x | 0.17x |
| 2018 | $3.31 Billion | $147.87 Billion | $19.12 Billion | 0.02x | 0.17x |
| 2019 | $3.05 Billion | $143.41 Billion | $19.20 Billion | 0.02x | 0.16x |
| 2020 | $3.34 Billion | $140.99 Billion | $18.69 Billion | 0.02x | 0.18x |
| 2021 | $2.12 Billion | $114.51 Billion | $9.25 Billion | 0.02x | 0.23x |
| 2022 | $1.94 Billion | $120.19 Billion | $9.66 Billion | 0.02x | 0.20x |
| 2023 | $1.93 Billion | $128.33 Billion | $11.74 Billion | 0.02x | 0.16x |
| 2024 | $1.75 Billion | $141.71 Billion | $13.97 Billion | 0.01x | 0.13x |
| 2025 | $1.64 Billion | $156.01 Billion | $21.76 Billion | 0.01x | 0.08x |
Competitor Companies of HPX by Market Capitalization
Companies near Hisamitsu Pharmaceutical Co. Inc in the global market cap rankings as of March 18, 2026.
Key companies related to Hisamitsu Pharmaceutical Co. Inc by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #423 globally with a market cap of $51.97 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #455 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #719 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #423 | Zoetis Inc | NYSE:ZTS | $51.97 Billion | $118.15 |
| #434 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.46 |
| #455 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #719 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
Hisamitsu Pharmaceutical Co. Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Hisamitsu Pharmaceutical Co. Inc's market cap moved from $2.65 Billion to $ 2.30 Billion, with a yearly change of 0.19%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €2.30 Billion | +40.35% |
| 2025 | €1.64 Billion | -6.56% |
| 2024 | €1.75 Billion | -8.96% |
| 2023 | €1.93 Billion | -0.74% |
| 2022 | €1.94 Billion | -8.44% |
| 2021 | €2.12 Billion | -36.60% |
| 2020 | €3.34 Billion | +9.81% |
| 2019 | €3.05 Billion | -7.98% |
| 2018 | €3.31 Billion | -5.69% |
| 2017 | €3.51 Billion | +6.75% |
| 2016 | €3.29 Billion | +24.04% |
| 2015 | €2.65 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 17th, 2026 the market cap of Hisamitsu Pharmaceutical Co. Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.30 Billion USD |
| MoneyControl | $2.30 Billion USD |
| MarketWatch | $2.30 Billion USD |
| marketcap.company | $2.30 Billion USD |
| Reuters | $2.30 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.